Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy

This population-based study found increased advanced therapies use partially because of the higher IBD prevalence observed during the study period, but with decreasing costs, mainly attributable to the significant use of anti-tumor necrosis factor αlpha biosimilars.